Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.
about
Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Animal models of Parkinson's disease: a gateway to therapeutics?Metabotropic glutamate receptor 5-negative allosteric modulators for the treatment of psychiatric and neurological disorders (2009-July 2013).Mavoglurant as a treatment for Parkinson's disease.Molecular imaging of levodopa-induced dyskinesias.mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.
P2860
Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Pharmacological characterizati ...... n L: -DOPA-induced dyskinesia.
@en
Pharmacological characterizati ...... n L: -DOPA-induced dyskinesia.
@nl
type
label
Pharmacological characterizati ...... n L: -DOPA-induced dyskinesia.
@en
Pharmacological characterizati ...... n L: -DOPA-induced dyskinesia.
@nl
prefLabel
Pharmacological characterizati ...... n L: -DOPA-induced dyskinesia.
@en
Pharmacological characterizati ...... n L: -DOPA-induced dyskinesia.
@nl
P2093
P2860
P1476
Pharmacological characterizati ...... n L: -DOPA-induced dyskinesia.
@en
P2093
Andreas Gravius
Andrzej Dekundy
Carsten Tober
Flora Mela
Jens Nagel
Martine van der Elst
Małgorzata Pietraszek
Mirko Hechenberger
Wojciech Danysz
P2860
P2888
P304
P356
10.1007/S00702-010-0526-0
P577
2010-12-16T00:00:00Z
P5875
P6179
1034679921